2023

Poster

OPN-6602, a dual EP300/CBP bromodomain inhibitor modulates androgen-driven transcription in mCRPC

  • AUTHORS Matusow, et al
  • Programs OPN-6602
Download PDF
Publication

Phase IIa Study of PLX2853 in Gynecologic Cancers with known ARID1A mutation and Phase Ib/IIa Study of PLX2853/Carboplatin in Platinum-resistant epithelial ovarian cancer

  • AUTHORS Duska, et al
  • Programs OPN-2853
https://ascopubs.org/doi/abs/10.1200/PO.23.00235
Poster

Phase 1b/2a clinical trial of the oral BET inhibitor PLX2853 as monotherapy for ARID1A mutated gynecologic cancers and in combination with carboplatin for platinum resistant ovarian cancer

  • AUTHORS Swisher, et al
  • Programs OPN-2853
Download PDF